Global Artificial Intelligence (AI) Partnering Deals: Trends, Players & Financials (2014-2020)

News provided by

May 18, 2020, 13:30 ET

DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Artificial Intelligence (AI) Partnering Terms and Agreements (2014-2020)" report has been added to ResearchAndMarkets.com's offering.

This report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

Global Artificial Intelligence Partnering Terms and Agreements includes:

Trends in artificial intelligence dealmaking in the biopharma industry since 2014
Analysis of artificial intelligence deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life artificial intelligence deals
Access to over 350 artificial intelligence deals
The leading artificial intelligence deals by value since 2014
Most active artificial intelligence dealmakers since 2014
The leading artificial intelligence partnering resources

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors artificial intelligence technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all artificial intelligence partnering deals announced since 2014 including financial terms where available including over 350 links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of artificial intelligence dealmaking and business activities.

Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading artificial intelligence deals since 2014. Deals are listed by headline value, signed by big pharma, most active artificial intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan to 2014, where a contract document is available in the public domain. The - Chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 lists artificial intelligence deals by technology type.
Chapter 7 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan to 2014. The - Chapter is organized by specific artificial intelligence technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Companies Mentioned

1ST Biotherapeutics
23andMe
A*STAR Bioinformatics Institute
A.I. Squared
A2A Pharmaceuticals
Abramson Cancer Center
AcuraStem
Adapt Analytics
Adaptive Biotechnologies
Adents
Adventus Ventures
Adynxx
Aether
Aiforia Technologies
AKESOgen
Alberta Innovates Bio Solutions
Alberta Innovates Technology Futures
Align Technology
AliveCor
Alliance For Clinical Trials In Oncology
ALS Association
Alverno Clinical Laboratories
American Sleep Apnea Association
Amgen
Amitech Solutions
Analytics Engines
Anthem
ArcherDX
Ares Genetics
Arm
ARUP Laboratories
AstraZeneca
Atomwise
Atrapos Therapeutics
ATUM
Auransa
Auron Therapeutics
Automation Anywhere
Avera Health
AXA PPP healthcare
Ayasdi
BASF
Bausch & Lomb
Bayer
Bay Labs
BCG Digital Ventures
BC Platforms
Becton Dickinson
BenevolentAI
Benson Hill Biosystems
Berg
BERG Analytics
BioBeats
BioBright
Biocept
Biorelate
Bioz
Blackford
BlackThorn Therapeutics
Blockshine Technology
Bloqcube
Body Labs
BrainScope
Brigham and Women's Hospital
Bristol-Myers Squibb
Broad Institute
Brown University
BullFrog AI
C4X Discovery
Cancer Genetics
Cannabics Pharmaceuticals
Cardinal Analytx Solutions
Cardiowise
Caresyntax
Carnegie Mellon University
CAS
Ceapro
Celgene
Cellgen Diagnostics
Centogene
Centre Leon Berard
Certis
Charles River Laboratories
CHDI Foundation
Chemi Pharmaceutical
Children's Hospital of Philadelphia
Children's National Health System
China Oncology Focus
Christian Doppler Research Association
City of Hope
CLEW Medical
Clinical Research Strategies
Clinigen
Cloudera
Cloud Pharmaceuticals
Cognetivity Neurosciences
Cognoa
Cohen Veterans Bioscience
Columbia University
Concerto HealthAI
Consortium AI
Control Flo Medical
COPAN
Covaris
CrystalGenomics
Cures Within Reach
Cyclica
Cytobank
CytoReason
Dacadoo
Dana-Farber Cancer Institute
DarwinHealth
DASH Analytics
Data2Life
Datavant
DEARhealth
DecisionQ
DEEP 6 AI

For more information about this report visit https://www.researchandmarkets.com/r/qdqu05

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets